Xentuzumab
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation[1].
Product Specifications
CAS Number
[1417158-65-6]
Product Name Alternative
BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody
UNSPSC
12352203
Target
IGF-1R
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/xentuzumab.html
Purity
99.71
Solubility
10 mM in DMSO
Smiles
[Xentuzumab]
Molecular Weight
(143.7 kDa)
References & Citations
[1]Weyer-Czernilofsky U, et al. Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models. Mol Cancer Ther. 2020 Apr;19 (4) :1059-1069.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
D2728-01J-ML490 100 µL
DLL4 (Delta-like Protein 4, Drosophila Delta Homolog 4, Delta4, UNQ1895/PRO4341) (MaxLight 490) discontinued
Ask
View Details 